CB4211 / CohBar - LARVOL DELTA

[VIRTUAL] CB4211, A NOVEL ANALOG OF MOTS-C, IMPROVES MARKERS OF LIVER INJURY AND METABOLISM IN OBESE SUBJECTS WITH NONALCOHOLIC FATTY LIVER DISEASE: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY (AASLD 2021) - "In obese subjects with NAFLD, 4 weeks of CB4211 treatment was safe and well tolerated. CB4211 treatment produced statistically significant reductions in biomarkers of liver injury, ALT and AST, compared to placebo and reduced fasting glucose levels, independent of reducing liver fat, with a trend to reduced body weight. These data support the further development CB4211, a first in class MOTS-c analog, as a potential treatment for NASH."

Clinical • Late-breaking abstract • Genetic Disorders • Hepatology • Liver Failure • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis • Obesity

"$CWBR CohBar Granted U.S. Patent Covering CB4211 Compositions and Use for Treating Nonalcoholic Steatohepatitis (NASH) https://t.co/7JIAf60vyp" (@otcdynamics)

Hepatology • Non-alcoholic Steatohepatitis

CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity (Market Watch) - P1a/1b, N=85, NCT03998514; Sponsor: CohBar, Inc.; "'Demonstrating significant reductions of this magnitude in both serum ALT and AST relative to placebo after only four weeks suggests a potential for improvement in liver health if we continue to see further improvements over a longer period of time in patients with NASH. Improvements in serum ALT and AST are key predictors of histologic response independent of liver fat change; CB4211 shows great promise as a potential candidate for further development in NASH for this growing epidemic of silent and progressive liver disease.'"

P1 data

[VIRTUAL] CohBar, Inc. (BIO 2021) - "CohBar’s efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases associated with the underlying impact of mitochondrial dysfunction. The company’s lead compound, CB4211, is in the Phase 1b stage of a Phase 1a/1b clinical trial for NASH and obesity."

Genetic Disorders • Hepatology • Metabolic Disorders • Non-alcoholic Steatohepatitis • Obesity

A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - P1a/1b; N=88; Completed; Sponsor: CohBar, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion • Hepatology • Non-alcoholic Fatty Liver Disease • Obesity

A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - P1a/1b; N=88; Active, not recruiting; Sponsor: CohBar, Inc.; Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatology • Non-alcoholic Fatty Liver Disease • Obesity

A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - P1a/1b; N=86; Recruiting; Sponsor: CohBar, Inc.; Suspended ➔ Recruiting

Clinical • Enrollment open • Hepatology • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis • Obesity

A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - P1a/1b; N=86; Suspended; Sponsor: CohBar, Inc.; Trial completion date: Feb 2020 ➔ Jan 2021; Recruiting ➔ Suspended; Trial primary completion date: Feb 2020 ➔ Jan 2021

Clinical • Trial completion date • Trial primary completion date • Trial suspension • Hepatology • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis • Obesity

A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - P1a/1b; N=86; Recruiting; Sponsor: CohBar, Inc.

Clinical • New P1 trial